## erbB-2 Antibody

Catalog No: #24888




Orders: order@signalwayantibody.com Support: tech@signalwayantibody.com


Description	Support: tech@signalwayantibody.com
Product Name	erbB-2 Antibody
Host Species	Chicken
Clonality	Polyclonal
Purification	Affinity chromatography purified via peptide column
Applications	ELISA WB IHC
Species Reactivity	Hu Ms Rt
Immunogen Type	Peptide
Immunogen Description	Raised against a 19 amino acid peptide near the carboxy terminus of human erbB-2.
Target Name	erbB-2
Other Names	erbB-2, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, NEU, NGL, HER2, HER-2, TKR1, CD340
Accession No.	Swiss-Prot:P04626Gene ID:2064
Uniprot	P04626
GeneID	2064;
Concentration	1mg/ml
Formulation	Supplied in PBS containing 0.02% sodium azide.
Storage	Can be stored at -20°C, stable for one year. As with all antibodies care should be taken to avoid repeated

freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

## Images



Western blot analysis of erbB-2 in rat liver tissue lysate with erbB-2 antibody at (A) 1 and (B) 2 ug/mL.



Immunohistochemistry of erbB-2 in human liver tissue with erbB-2 antibody at 2.5  $\mbox{ug/mL}$ .

## Background

The ErbB family consists of four closely related tyrosine kinase receptors that act as potent mediators of normal cell growth and development. Aberrant expression or function of one or more of these receptors can play a major role in the development and evolution of cancer. ErbB-2, also known as HER2, has been implicated in the evolution of both breast and gastric cancers, and is evident in other cancer types such as ovarian and salivary gland tumors. ErbB-2 possesses an active tyrosine kinase domain, but no direct ligand has been identified yet. ErbB-2 is the preferred binding partner to the other members of the ErbB family and is thought to act primarily through the Ras-MAPK, Pl3k-PKB/Akt, and PLC-PKC signaling pathways. Numerous anti-cancer strategies have been employed against erbB-2, such as antibody-based therapies to prevent ligand binding or receptor activation through dimerization, antibody-dependent cell mediated cytotoxicity, in addition to direct kinase inhibition to prevent molecular activation/downstream signaling.

Note: This product is for in vitro research use only